(A)


- 102 -


- **Almawi, WY.; Melemedjian, OK.; Spruance, SL. and Esmann** : Negative regulation of nuclear factor-kappaB activation and function by glucocorticoids. J Mol Endocrinol 2002 ; 28 :69–78.


- **Anderson, KV. and Nusslein, VC.** : Information for the dorsal ventral pattern of the Drosophila embryo is stored as maternal mRNA. Nature 1984 ; 7: 311-223.

- **Andersen, N ; Hawn, TR.; Smith, KD.; Nachman, A.; Lampano, AE. and Uematsu , S.** : Cutting edge: Tlr5/- mice are more susceptible to Escherichia coli urinary tract infection. J Immunol 2007 ;178: 4717–4720.


(B)


• Bartfai, T.; Parker, LC.; Wilson, AG. and Whyte, MK.: A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses. Proc Natl Acad Sci USA 2003;100:7971–7976.


• **Blanco, AM.; Valles, SL.; Pascual, M. and Guerri, C.:** Involvement of TLR4/type I IL-1 receptor signaling in the induction of inflammatory mediators and cell death induced by ethanol in cultured astrocytes. J Immunol 2005; 175:6893–6899.

• **Blander, JM. and Medzhitov, R.:** Regulation of phagosome maturation by signals from TLRs. Science 2004; 304: 1014–1018.

• **Blander, JM. and Medzhitov, R.:** Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006; 440: 808–12.

• **Bouis, DA.; Popova, TG. and Takashima, A.:** Dendritic cells phagocytose and are activated by Treponema pallidum. Infect Immun 2001; 69: 518–528.

• **Bowie, A.; Kiss-Toth, E.; Symons, JA.; Smith, GL.; Dower, SK. and O’Neill, LA.:** A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc Natl Acad Sci USA 2000; 97: 10162–10167.


• **Bucov, M.:** A role of cytokines in local and systemic inflammation, and septic shock. Vnitr Lek 2002; 48: 755-762.
(C)


(D)


• Di, ML.; Cinque, B.; Cupelli, F. and Giuliani, M.: Increase of skinceramide levels in aged subjects following a short-term topical


(E)


(F)


- Finlay, BB. and Hancock, RE.: Can innate immunity be enhanced to treat microbial infections?. Nat Rev Microbiol 2004; 2: 497-504.


(G)


(H)


• Harrison, CJ.; Miller, RL. and Bernstein, DI.: Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine. Vaccine 2001;19: 1820–1826.


(I)


(J)


(K)


(L)


(M)


• Michelsen, KS.; Aicher, A.; Mohaupt, M.; Dimmeler, S. and Kirschning, CJ. :The role of toll-like receptors in bacteria-induced maturation of murine dendritic cells (DCS). Peptidoglycan and
lipoteichoic acid are inducers of DC maturation and require TLR2.


(N)


• Netea, MG.; Van der, GC.; Van der, JW. and Kullberg, BJ.: Recognition of fungal pathogens by Toll-like receptors. Eur J Clin Microbiol Infect Dis 2004; 23: 672–676.

\((O)\)


(R)


(S)


• **Sergio, AA.; Caroll, JB.; Isabel, MA.; Paulina, S. and Marcella** :Toll like receptors are Key Participants in Innate Immune Responses . Biol Res 2007; 40: 97-112.


(T)


• Tatti, S.; Belardi, G. and Marini, M.: Consenso en la metodologia de diagnóstica y terapeutica para las verrugas


- **Tian, J.; Vielhauer, V. and Mayadas, T.** : Regulation of TLR9 dependent DNA immune complex mediated cell activation by high mobility group box protein 1 and the receptor for advanced glycation end products (RAGE). Nat Immunol 2007;8 :780 .


(U)


(V)


- **Viglianti, GA.; Lau, CM.; Hanley, TM.; Miko, BA.; Shlomchik MJ. and Marshak, RA.** : Activation of autoreactive B cells by CpG dsDNA. Immunity 2003 ;19:837 847.


(W)

• Wagner, TL.; Ahonen, CL.; Couture, AM.; Gibson, SJ.; Miller, RL.; Vasilakos, JP. and Tomai, MA. : Modulation of Th1 and Th2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol 1999; 191 : 10–19.

• Weeratna, RD.; Bourne, LL.; Sullivan, SM. and Krieg, AM. : Combination of a new TLR9 agonist immunomodulator (CpG-7909) and paclitaxel for treatment of metastatic Lewis Lung Carcinoma. ASCO annual meeting proceedings 2004; 22: 7346.


(Y)


(Z)


